Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study
Chronic obstructive pulmonary disease (COPD) is often caused by cigarette smoking, but genetic predisposition also influences COPD susceptibility. The purpose of this study is to identify genetic factors that predispose some individuals to develop COPD.
Chronic Obstructive Pulmonary Disease
|Study Design:||Observational Model: Family-Based
Time Perspective: Cross-Sectional
|Official Title:||Genetic Epidemiology of Severe, Early-Onset Chronic Obstructive Pulmonary Disease|
- No Primary Outcome [ Designated as safety issue: No ]Since this is an observational study, there are no primary outcomes
Biospecimen Retention: Samples With DNA
DNA, Serum, Plasma, Buccal Brushings, and Urine
|Study Start Date:||July 1994|
|Estimated Study Completion Date:||July 2018|
|Estimated Primary Completion Date:||July 2018 (Final data collection date for primary outcome measure)|
Severe, early-onset COPD subjects that bring the family into the study
Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.
Chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in the United States, affects millions of people around the world. COPD, which can include both emphysema and chronic bronchitis, affects the lungs making it very difficult to breathe. Cigarette smoking is the most common risk factor for developing COPD; however, only 15% to 20% of smokers develop COPD in their lifetimes. The onset of COPD also varies greatly from person to person; while some people do not develop respiratory symptoms until later in life, there are others who develop severe COPD at a very early age. Prior research has led to the discovery of the alpha-1 antitrypsin protein deficiency in association with COPD development. This discovery has generated further interest toward studying other genetic factors which may also affect an individual's likelihood of developing COPD. Therefore, the purpose of the Boston Early-Onset COPD study is to gain a better understanding of COPD risk factors in order to establish new possible methods of treatment for people affected by COPD.
For this study we are enrolling individuals affected with severe COPD (52 years old or younger with an FEV1 < 40%) and their family members. Each participant will attend one study visit that involves a respiratory questionnaire, a breathing test, and blood draw. This visit can be completed at the participant's home, in the hospital, or by long distance data collection (phone interview, local breathing tests, and local blood draw with mailed samples), whichever is preferred.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01177618
|Contact: Edwin K. Silverman, M.D., Ph.D.||email@example.com|
|United States, Massachusetts|
|Brigham and Women's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Josh Medeiros 617-525-2075 firstname.lastname@example.org|
|Contact: Sandra Melanson 617-525-2128 email@example.com|
|Principal Investigator: Edwin K. Silverman, M.D., Ph.D.|
|Sub-Investigator: Dawn L. DeMeo, M.D.|
|Sub-Investigator: Craig P. Hersh, M.D.|